Outlook Therapeutics Q1 net loss $11.2M; NORSE EIGHT underway, SPA agreed, $172M financing

Outlook Therapeutics, Inc.

2024-Q1 EPS reported -$0.04

Net loss for Q1 FY2024 was $11.2M ($0.04/sh), compared to $18.7M ($0.08/sh) in prior year.
Cash and equivalents at Dec 31, 2023: $10.4M; private placements for up to $172M (subject to shareholder approval).
FDA SPA agreed on NORSE EIGHT protocol; first subject dosed Jan 2024. Success would satisfy second clinical trial requirement from CRL.
BLA resubmission for ONS-5010 expected by end of CY2024; EU MAA decision targeted first half 2024.
Company working to resolve CMC comments from CRL; expects resolution before NORSE EIGHT completion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Outlook Therapeutics, Inc. reported first fiscal quarter ended December 31, 2023 results: net income $11.2 million, EPS $0.04 per basic and diluted share.

Period: first fiscal quarter ended December 31, 2023
Net income: $11.2 million
EPS: $0.04 per basic and diluted share
Result: reported results

Exact text from the filing

For the fiscal first quarter ended December 31, 2023, Outlook Therapeutics reported a net loss attributable to common stockholders of $11.2 million, or $0.04 per basic and diluted share

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-023842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.